Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1720

Sort by

Sort Order Select

Journal Articles

CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Blood Adv bloodadvances.2024013236.

https://doi.org/10.1182/bloodadvances.2024013236

Published: 2024

Includes: Supplemental data

Journal Articles

Alliance A061202: Ixazomib, pomalidomide and dexamethasone for lenalidomide-refractory multiple myeloma in first relapse

Peter M Voorhees, Vera Suman, Yvonne A. Efebera, Noopur Raje, Sascha A Tuchman, Cesar Rodriguez, Jacob P Laubach, Misty Bova-Solem, Destin Carlisle, Saad Z Usmani, Philip L. McCarthy, Paul G. Richardson

Blood Adv bloodadvances.2024013623.

https://doi.org/10.1182/bloodadvances.2024013623

Published: 2024

Includes: Supplemental data

Journal Articles

Hodgkin Lymphoma Involving the Extra-Axial CNS: An AHOD1331, PHL-C1 and PHL-C2 Report From the COG and EuroNet-PHL

Reena Pabari, Kathleen M McCarten, Jamie E Flerlage, Hollie A Lai, Christine Mauz-Koerholz, Karin Dieckmann, Monica Palese, Sue C Kaste, Sharon M Castellino, Kara M Kelly, Dietrich Stoevesandt, Lars Kurch

Blood Adv bloodadvances.2023012346.

https://doi.org/10.1182/bloodadvances.2023012346

Published: 2024

Includes: Supplemental data

Journal Articles

Improving infection reporting in hematology treatment trials

Benjamin W. Teh, Gemma Reynolds, Dr, Malgorzata Mikulska, Nicolas J. Mueller, Monica A Slavin

Blood Adv bloodadvances.2024013859.

https://doi.org/10.1182/bloodadvances.2024013859

Published: 2024

Journal Articles

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Chijioke Nze, Clark R. Andersen, Amy A. Ayers, Jason Westin, Michael Wang, Swaminathan Iyer, Sairah Ahmed, Chelsea Pinnix, Francisco Vega, Lynne Nguyen, Lorna McNeill, Loretta J. Nastoupil, Kehe Zhang, Cici X. Bauer, Christopher R. Flowers

Blood Adv (2024) 8 (14): 3825–3837.

https://doi.org/10.1182/bloodadvances.2023011040

Published: 2024

Includes: Supplemental data

Journal Articles

Aspiring to equity: race vs ethnicity in clinical research

Nada Hamad

Blood Adv (2024) 8 (14): 3823–3824.

https://doi.org/10.1182/bloodadvances.2024013028

Published: 2024

Journal Articles

Soiled soil

Frederick R. Appelbaum

Blood Adv (2024) 8 (14): 3847–3848.

https://doi.org/10.1182/bloodadvances.2024013145

Published: 2024

Journal Articles

Long-term Clinical Outcomes of Prophylaxis With a rFVIIIFc or rFIXFc in Adults 50+ Years of Age With Hemophilia A or B

Doris Quon, Shannon Jackson, María Teresa Álvarez-Román, Umer Khan, Sandra Milena Casiano, Margaret V Ragni, Savita Rangarajan

Blood Adv bloodadvances.2023012462.

https://doi.org/10.1182/bloodadvances.2023012462

Published: 2024

Includes: Supplemental data

Journal Articles

Unexpected Diagnosis of WHIM syndrome in Refractory Autoimmune Cytopenia

Yolanda Garcia-Carmona, Jose Luis Chavez, Yael Gernez, Julia T. Geyer, James B Bussel, Charlotte Cunningham-Rundles, MD PhD

Blood Adv bloodadvances.2024013301.

https://doi.org/10.1182/bloodadvances.2024013301

Published: 2024

Includes: Supplemental data

Journal Articles

A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Meletios-Athanasios A. Dimopoulos, Daniel Coriu, Sosana Delimpasi, Ivan Spicka, Terry E Upchurch, Belle Fang, Rakhshandra Talpur, Edward Anthony Faber, Jr, Meral Beksac, Xavier Leleu

Blood Adv bloodadvances.2024013101.

https://doi.org/10.1182/bloodadvances.2024013101

Published: 2024

Includes: Supplemental data

Journal Articles

Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock

Giorgio Minotti

Blood Adv (2024) 8 (14): 3810–3812.

https://doi.org/10.1182/bloodadvances.2024013348

Published: 2024

Journal Articles

Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis

Jasmine Singh, Nancy Li, Elham Ashrafi, Le Thi Phuong Thao, David J. Curtis, Erica M. Wood, Zoe K. McQuilten

Blood Adv (2024) 8 (14): 3771–3784.

https://doi.org/10.1182/bloodadvances.2024013228

Published: 2024

Includes: Supplemental data

Journal Articles

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16

Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer

Blood Adv (2024) 8 (14): 3721–3730.

https://doi.org/10.1182/bloodadvances.2023012539

Published: 2024

Includes: Supplemental data

Journal Articles

Flow cytometric profiles with CD7 and CADM1 in CD4 + T cells are promising indicators for prognosis of aggressive ATL

Koji Jimbo, Toyotaka Kawamata, Yoshihiro Inamoto, Ayumu Ito, Kazuaki Yokoyama, Aki Sato, Takahiro Fukuda, Kaoru Uchimaru, Yasuhito Nannya

Blood Adv (2024) 8 (14): 3760–3770.

https://doi.org/10.1182/bloodadvances.2024013089

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz, Alejandro Martin Martin Garcia-Sancho, Ranjana H Advani, Josep Maria Roncero Vidal, Raquel De Oña, Ana Marin-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, MD, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss

Blood Adv bloodadvances.2024012806.

https://doi.org/10.1182/bloodadvances.2024012806

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 mRNA Vaccination Responses in Individuals With Sickle Cell Disease: ASH RC Sickle Cell Research Network Study

Blood Adv bloodadvances.2024013878.

https://doi.org/10.1182/bloodadvances.2024013878

Published: 2024

Journal Articles

Phase II study of a longitudinal rehabilitation program for allogeneic blood and marrow transplantation patients

Samantha Tam, Shabbir MH Alibhai, Dima El Hassanieh, Rajat Kumar, Jonas I. Mattsson, Eshetu G. Atenafu, PStat, Lisa Avery, Lori J. Bernstein, Eugene Chang, David Michael Langelier, Paty Lopez, Jennifer Michelle Jones

Blood Adv bloodadvances.2024012968.

https://doi.org/10.1182/bloodadvances.2024012968

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Mirian Brink, Francien Huisman, Frederik O. Meeuwes, Marjolein W. M. van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F. J. Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Arjan Diepstra, Tjeerd J. F. Snijders, Gerwin Huls, Joost S. P. Vermaat, Wouter J. Plattel, Marcel Nijland

Blood Adv (2024) 8 (14): 3619–3628.

https://doi.org/10.1182/bloodadvances.2023012531

Published: 2024

Includes: Supplemental data

Journal Articles

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma

Giuseppe Gritti, Anton Belousov, James Relf, Mark Dixon, Maneesh Tandon, Krishna Komanduri

Blood Adv (2024) 8 (14): 3615–3618.

https://doi.org/10.1182/bloodadvances.2023011089

Published: 2024

Includes: Supplemental data

Journal Articles

D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation

Armando Tripodi, Marco Capecchi, Erica Scalambrino, Marigrazia Clerici, Barbara Scimeca, Pasquale Agosti, Paolo Bucciarelli, Flora Peyvandi

Blood Adv (2024) 8 (14): 3612–3614.

https://doi.org/10.1182/bloodadvances.2024013193

Published: 2024

NARROW

CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Alliance A061202: Ixazomib, pomalidomide and dexamethasone for lenalidomide-refractory multiple myeloma in first relapse

Hodgkin Lymphoma Involving the Extra-Axial CNS: An AHOD1331, PHL-C1 and PHL-C2 Report From the COG and EuroNet-PHL

Improving infection reporting in hematology treatment trials

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Aspiring to equity: race vs ethnicity in clinical research

Soiled soil

Long-term Clinical Outcomes of Prophylaxis With a rFVIIIFc or rFIXFc in Adults 50+ Years of Age With Hemophilia A or B

Unexpected Diagnosis of WHIM syndrome in Refractory Autoimmune Cytopenia

A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock

Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16

Flow cytometric profiles with CD7 and CADM1 in CD4 + T cells are promising indicators for prognosis of aggressive ATL

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma

COVID-19 mRNA Vaccination Responses in Individuals With Sickle Cell Disease: ASH RC Sickle Cell Research Network Study

Phase II study of a longitudinal rehabilitation program for allogeneic blood and marrow transplantation patients

Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma

D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only